Head & Neck Cancer

Protocol #SponsorProtocol Title
NCT02358031

Merck Sharp & Dohme Corp.
3475-048, 2014-003698-41
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
NCT01772004

EMD Serono
EMR 100070-001, 2013-002834-19
A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
NCT02605967Novartis Pharamaceuticals
CPDR001X2201
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients with Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment

Northwest Georgia Oncology Centers‘ (NGOC) physicians work with specialty teams of ENT surgeons and radiation oncologists to provide expert care in cancer of the head and neck.